These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 20610831)

  • 1. FTY720 and central memory: out of sight, out of mind.
    Slavin AJ; Zamvil SS
    Neurology; 2010 Aug; 75(5):388-9. PubMed ID: 20610831
    [No Abstract]   [Full Text] [Related]  

  • 2. Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis.
    Mehling M; Lindberg R; Raulf F; Kuhle J; Hess C; Kappos L; Brinkmann V
    Neurology; 2010 Aug; 75(5):403-10. PubMed ID: 20592255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trial watch: Phase III promise for oral multiple sclerosis therapy.
    Nat Rev Drug Discov; 2009 Feb; 8(2):98. PubMed ID: 19180099
    [No Abstract]   [Full Text] [Related]  

  • 4. ACS chemical neuroscience molecule spotlight on gilenya (fingolimod; FTY720).
    Hopkins CR
    ACS Chem Neurosci; 2011 Mar; 2(3):116-7. PubMed ID: 22778861
    [No Abstract]   [Full Text] [Related]  

  • 5. [Fingolimod therapy in multiple sclerosis--the issue of the pathomechanism].
    Tar L; Vécsei L
    Ideggyogy Sz; 2012 Mar; 65(3-4):83-100. PubMed ID: 23136726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recurrent varicella following steroids and fingolimod in a Multiple Sclerosis patient.
    Ferraro D; De Biasi S; Vitetta F; Simone AM; Federzoni L; Borghi V; Cossarizza A; Nichelli PF; Sola P
    J Neuroimmune Pharmacol; 2013 Dec; 8(5):1059-61. PubMed ID: 24163092
    [No Abstract]   [Full Text] [Related]  

  • 7. The impact of fingolimod (FTY720) in neuroimmunologic diseases: mechanisms beyond immunomodulation.
    Haghikia A; Gold R
    Am J Pathol; 2010 Jun; 176(6):2599-601. PubMed ID: 20395429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention, but not cure, of autoimmune diabetes in a NOD.scid transfer model by FTY720 despite effective modulation of blood T cells.
    Morris MA; McDuffie M; Nadler JL; Ley K
    Autoimmunity; 2011 Mar; 44(2):115-28. PubMed ID: 20695767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of oral agent in the treatment of multiple sclerosis: how the first available oral therapy, fingolimod will change therapeutic paradigm approach.
    Gasperini C; Ruggieri S
    Drug Des Devel Ther; 2012; 6():175-86. PubMed ID: 22888218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A plan for risk management in the treatment of multiple sclerosis with gilenia (fingolimod)].
    Popova NF
    Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(2 Pt 2):110-3. PubMed ID: 21916166
    [No Abstract]   [Full Text] [Related]  

  • 11. FTY720, a novel immunosuppressant, prolongs rat skin allograft survival by decreasing T-cell infiltration into grafts.
    Yanagawa Y; Hoshino Y; Kataoka H; Kawaguchi T; Ohtsuki M; Sugahara K; Chiba K
    Transplant Proc; 1999; 31(1-2):1227-9. PubMed ID: 10083548
    [No Abstract]   [Full Text] [Related]  

  • 12. Ascomycete derivative to MS therapeutic: S1P receptor modulator FTY720.
    Hiestand PC; Rausch M; Meier DP; Foster CA
    Prog Drug Res; 2008; 66():361, 363-81. PubMed ID: 18416311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple sclerosis: closing in on an oral treatment.
    Martin R
    Nature; 2010 Mar; 464(7287):360-2. PubMed ID: 20237554
    [No Abstract]   [Full Text] [Related]  

  • 14. Current perspectives on FTY720.
    Martini S; Peters H; Böhler T; Budde K
    Expert Opin Investig Drugs; 2007 Apr; 16(4):505-18. PubMed ID: 17371198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fingolimod and sphingosine-1-phosphate--modifiers of lymphocyte migration.
    Massberg S; von Andrian UH
    N Engl J Med; 2006 Sep; 355(11):1088-91. PubMed ID: 16971715
    [No Abstract]   [Full Text] [Related]  

  • 16. Prolongation of concordant xenograft survival by treatment with FTY720.
    Miyata Y; Ohdan H; Noriyuki T; Shintaku S; Shibata S; Yamamoto H; Fan XH; Fudaba Y; Yoshioka S; Asahara T; Fukuda Y; Dohi K
    Transplant Proc; 1998 Dec; 30(8):4163-5. PubMed ID: 9865334
    [No Abstract]   [Full Text] [Related]  

  • 17. [FTY720 (Fingolimod) as a new therapeutic option for multiple sclerosis].
    Klatt J; Hartung HP; Hohlfeld R
    Nervenarzt; 2007 Oct; 78(10):1200-8. PubMed ID: 17668161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New drugs may improve, complicate treatment for multiple sclerosis.
    Link H; Martin R
    Nat Med; 2010 Mar; 16(3):272. PubMed ID: 20208513
    [No Abstract]   [Full Text] [Related]  

  • 19. Targeting cells in motion: migrating toward improved therapies.
    Griffith JW; Luster AD
    Eur J Immunol; 2013 Jun; 43(6):1430-5. PubMed ID: 23580465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relapse of experimental autoimmune encephalomyelitis after discontinuation of FTY720 (Fingolimod) treatment, but not after combination of FTY720 and pathogenic autoantigen.
    Yoshida Y; Tsuji T; Fujita T; Kohno T
    Biol Pharm Bull; 2011; 34(6):933-6. PubMed ID: 21628899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.